BB's Stock Haven

[dirkv]

Organovo Holdings, Inc. (ONVO) : 0.9701-0.0999 (-9.34%)

Shares Outstanding 11.39M
Float 9.87M

https://www.otcmarkets.com/filing/conv_pdf?id=17496946&guid=LJQ-kapzYH7fJth

May 01, 2024 0.9800 1.0200 0.9700 0.9701 0.9701 235,655
Apr 30, 2024 1.0500 1.0900 1.0300 1.0700 1.0700 69,200
Apr 29, 2024 0.9900 1.0600 0.9900 1.0400 1.0400 111,800
Apr 26, 2024 0.9900 1.0300 0.9800 1.0000 1.0000 139,300
Apr 25, 2024 0.9800 1.0200 0.9800 0.9900 0.9900 72,900
Apr 24, 2024 0.9900 1.0300 0.9900 1.0000 1.0000 117,000
Apr 23, 2024 1.0000 1.0600 1.0000 1.0000 1.0000 127,100
Apr 22, 2024 1.0700 1.1200 1.0100 1.0300 1.0300 297,900
Apr 19, 2024 1.1500 1.1900 1.1000 1.1000 1.1000 275,200
Apr 18, 2024 1.1000 1.2900 1.0900 1.1500 1.1500 579,000
Apr 17, 2024 1.1100 1.2100 1.0500 1.1200 1.1200 550,900
Apr 16, 2024 1.2800 1.3000 1.1000 1.1500 1.1500 1,941,500
Apr 15, 2024 1.6600 1.7400 1.2000 1.3500 1.3500 53,785,500
Apr 12, 2024 1.0200 1.0400 1.0000 1.0100 1.0100 52,700


Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
We believe Organovo is at a good spot for potential investors, with positive test results providing confidence that the company is on the right track.


Apr 01, 2024 1.0300 1.7400 0.9800 1.0700 1.0700 58,338,700
Mar 01, 2024 1.0200 1.2400 0.9800 1.0300 1.0300 2,902,500
Feb 01, 2024 1.0400 1.1700 0.8900 1.0200 1.0200 2,468,800
Jan 01, 2024 1.1000 1.2700 1.0000 1.0200 1.0200 2,263,200
Dec 01, 2023 1.1500 1.3900 1.0500 1.1100 1.1100 6,634,400
Nov 01, 2023 1.1000 2.0500 1.1000 1.1700 1.1700 5,603,100
Oct 01, 2023 1.2100 1.4300 1.0500 1.0600 1.0600 479,500
Sep 01, 2023 1.2000 1.6400 1.0000 1.2500 1.2500 1,245,100
Aug 01, 2023 1.6500 1.6700 1.1400 1.2000 1.2000 685,800
Jul 01, 2023 1.6200 1.9600 1.6200 1.6700 1.6700 535,400
Jun 01, 2023 1.7100 1.9500 1.6100 1.6900 1.6900 478,300
May 01, 2023 1.9500 2.0300 1.7000 1.7000 1.7000 440,700
Apr 01, 2023 2.2000 2.2500 1.7500 1.9500 1.9500 476,600
Mar 01, 2023 2.3200 2.3700 1.7400 2.1900 2.1900 1,132,600
Feb 01, 2023 1.6000 3.4000 1.6000 2.3700 2.3700 5,776,700
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Dec 01, 2022 1.5200 1.9000 1.3700 1.4100 1.4100 470,700
Nov 01, 2022 1.7000 1.7100 1.4500 1.5100 1.5100 392,100
Oct 01, 2022 2.1000 2.2300 1.6000 1.6400 1.6400 523,400
Sep 01, 2022 2.6200 2.8600 1.8700 2.0500 2.0500 3,562,200
Aug 01, 2022 2.9000 3.7200 2.2800 2.3600 2.3600 1,104,600
Jul 01, 2022 1.8800 3.6300 1.7500 2.9400 2.9400 4,779,500
Jun 01, 2022 2.3900 2.5400 1.7100 1.7700 1.7700 652,500
May 01, 2022 2.9200 2.9400 2.2400 2.4100 2.4100 439,900
Apr 01, 2022 3.7200 3.7900 2.8400 2.8700 2.8700 450,800
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2022 3.1600 3.6400 2.6500 3.5600 3.5600 834,600
Jan 01, 2022 3.7300 4.4800 2.5600 3.1200 3.1200 1,288,000
Dec 01, 2021 4.8600 5.2000 3.6300 3.6300 3.6300 1,480,200
Nov 01, 2021 6.1800 6.5900 4.4100 4.7900 4.7900 1,478,300
Oct 01, 2021 6.7800 6.9700 5.8800 6.2100 6.2100 1,031,100
Sep 01, 2021 7.7100 8.1300 6.5000 6.8000 6.8000 950,200
Aug 01, 2021 7.5800 8.3000 6.0500 7.6600 7.6600 1,757,000
Jul 01, 2021 9.4700 9.5600 7.2600 7.6700 7.6700 1,186,900
Jun 01, 2021 9.3700 9.8900 7.7100 9.4000 9.4000 4,603,200
May 01, 2021 8.5600 11.2500 6.5000 9.4000 9.4000 9,836,900
Apr 01, 2021 10.0300 10.4200 7.5300 8.5400 8.5400 2,893,200
Mar 01, 2021 13.3300 14.0900 8.2400 9.6400 9.6400 5,366,500
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
Jan 01, 2021 12.4600 17.4000 10.6300 12.7900 12.7900 6,828,400
Dec 01, 2020 8.5500 20.4900 7.0300 12.3000 12.3000 7,949,400
Nov 01, 2020 8.9800 10.6800 8.4100 8.5500 8.5500 1,889,700
Oct 01, 2020 7.9000 11.6600 6.8600 8.5800 8.5800 3,889,700
Sep 01, 2020 9.1800 9.8900 6.0200 7.9100 7.9100 2,242,700
Aug 01, 2020 13.0000 15.6000 7.1900 9.1200 9.1200 2,053,350
Jul 01, 2020 11.2000 17.4000 11.2000 13.2000 13.2000 1,603,005
Jun 01, 2020 13.2000 15.6000 9.4000 11.0000 11.0000 1,163,685
May 01, 2020 8.4000 18.6000 7.8000 12.6000 12.6000 2,742,405
Apr 01, 2020 7.4000 9.0000 4.8000 8.4000 8.4000 822,850
Mar 01, 2020 6.2000 9.0000 3.8000 8.2000 8.2000 869,975
Feb 01, 2020 6.4000 7.2000 5.2000 6.4000 6.4000 412,345
Jan 01, 2020 7.4000 10.2000 6.2000 6.4000 6.4000 713,350
Dec 01, 2019 10.4000 13.0000 7.0000 7.2000 7.2000 776,335
Nov 01, 2019 6.2000 10.4000 6.2000 10.0000 10.0000 822,955
Oct 01, 2019 5.2000 6.8000 5.0000 6.0000 6.0000 628,355
Sep 01, 2019 5.0000 6.4000 4.8000 5.2000 5.2000 388,390
Aug 01, 2019 8.2000 8.8000 4.4000 5.2000 5.2000 1,077,395
Jul 01, 2019 10.6000 11.0000 8.2000 8.2000 8.2000 763,825
Jun 01, 2019 12.2000 12.2000 8.0000 10.4000 10.4000 2,801,700
May 01, 2019 19.8000 21.0000 7.4000 11.0000 11.0000 4,216,855
Apr 01, 2019 20.6000 21.0000 19.2000 20.0000 20.0000 569,565
Mar 01, 2019 21.2000 23.2000 19.2000 19.8000 19.8000 875,270
Feb 01, 2019 20.2000 23.6000 19.0000 21.2000 21.2000 593,370
Jan 01, 2019 18.6000 23.2000 18.2000 20.2000 20.2000 585,970
Dec 01, 2018 19.8000 21.2000 18.0000 19.2000 19.2000 535,770
Nov 01, 2018 20.4000 25.4000 18.0000 19.4000 19.4000 513,085
Oct 01, 2018 22.8000 23.8000 19.8000 20.2000 20.2000 548,380
Sep 01, 2018 26.0000 26.2000 22.4000 23.0000 23.0000 504,515
Aug 01, 2018 23.8000 27.6000 21.0000 25.8000 25.8000 717,665
Jul 01, 2018 27.4000 28.8000 21.6000 23.8000 23.8000 656,945
Jun 01, 2018 36.6000 38.4000 25.2000 28.0000 28.0000 1,331,290
May 01, 2018 25.0000 41.8000 23.0000 39.4000 39.4000 1,589,720
Apr 01, 2018 20.6000 26.4000 18.2000 24.8000 24.8000 1,031,170
Mar 01, 2018 20.2000 24.8000 19.4000 20.6000 20.6000 723,335
Feb 01, 2018 27.8000 30.8000 18.6000 20.2000 20.2000 1,151,910
Jan 01, 2018 27.0000 30.0000 26.4000 28.0000 28.0000 1,155,930
Dec 01, 2017 30.0000 34.0000 26.4000 26.8000 26.8000 1,773,095
Nov 01, 2017 32.8000 34.6000 26.6000 30.2000 30.2000 956,150
Oct 01, 2017 44.4000 45.6000 26.4000 31.8000 31.8000 2,016,175
Sep 01, 2017 41.6000 47.6000 39.0000 44.4000 44.4000 923,775
Aug 01, 2017 47.2000 47.2000 35.0000 41.6000 41.6000 1,005,585
Jul 01, 2017 52.6000 54.4000 45.8000 46.8000 46.8000 641,220
Jun 01, 2017 56.6000 60.6000 51.0000 52.6000 52.6000 943,360
May 01, 2017 58.6000 63.8000 52.8000 56.6000 56.6000 1,008,445
Apr 01, 2017 63.4000 63.8000 51.6000 58.0000 58.0000 848,715
Mar 01, 2017 63.0000 65.2000 55.2000 63.6000 63.6000 1,138,240
Feb 01, 2017 74.6000 77.0000 56.8000 62.4000 62.4000 1,655,225
Jan 01, 2017 70.8000 78.4000 67.0000 73.8000 73.8000 1,266,630
Dec 01, 2016 60.2000 81.6000 57.2000 67.8000 67.8000 1,932,080
Nov 01, 2016 52.6000 68.0000 50.0000 60.4000 60.4000 1,133,225
Oct 01, 2016 76.0000 82.8000 49.6000 49.8000 49.8000 1,453,975
Sep 01, 2016 76.8000 85.6000 73.8000 75.8000 75.8000 757,900
Aug 01, 2016 88.0000 99.8000 74.6000 77.2000 77.2000 1,330,340
Jul 01, 2016 74.8000 88.0000 73.6000 85.6000 85.6000 1,310,520
Jun 01, 2016 58.0000 74.8000 55.4000 74.4000 74.4000 979,690
May 01, 2016 54.4000 61.0000 48.2000 58.4000 58.4000 427,830
Apr 01, 2016 43.4000 59.6000 42.2000 54.4000 54.4000 704,230
Mar 01, 2016 46.0000 52.8000 40.0000 43.4000 43.4000 777,025
Feb 01, 2016 39.4000 48.8000 34.8000 45.0000 45.0000 705,540
Jan 01, 2016 48.8000 51.2000 32.0000 39.2000 39.2000 878,200
Dec 01, 2015 68.0000 69.6000 49.8000 49.8000 49.8000 807,620
Nov 01, 2015 60.0000 69.4000 57.4000 67.8000 67.8000 709,990
Oct 01, 2015 53.8000 69.0000 47.4000 60.2000 60.2000 1,159,270
Sep 01, 2015 53.0000 81.6000 48.4000 53.6000 53.6000 1,624,565
Aug 01, 2015 67.0000 73.0000 38.0000 54.6000 54.6000 1,803,630
Jul 01, 2015 76.6000 82.6000 65.2000 67.6000 67.6000 1,557,020
Jun 01, 2015 100.2000 116.4000 72.8000 75.4000 75.4000 2,259,105
May 01, 2015 90.2000 103.4000 88.4000 100.2000 100.2000 847,660
Apr 01, 2015 79.8000 109.0000 70.0000 90.8000 90.8000 3,083,420
Mar 01, 2015 118.8000 122.4000 65.8000 70.8000 70.8000 1,918,625
Feb 01, 2015 127.0000 131.4000 116.2000 118.4000 118.4000 813,940
Jan 01, 2015 143.2000 148.4000 120.2000 128.6000 128.6000 715,755
Dec 01, 2014 127.2000 153.6000 107.0000 145.0000 145.0000 1,635,865
Nov 01, 2014 130.2000 148.0000 122.8000 126.2000 126.2000 854,790
Oct 01, 2014 127.4000 133.6000 107.8000 130.8000 130.8000 1,098,555
Sep 01, 2014 157.0000 157.0000 123.4000 127.4000 127.4000 941,075
Aug 01, 2014 150.2000 167.0000 142.0000 155.6000 155.6000 973,065
Jul 01, 2014 168.8000 185.0000 137.0000 151.4000 151.4000 1,644,960
Jun 01, 2014 143.0000 182.0000 125.2000 167.0000 167.0000 1,806,020
May 01, 2014 118.4000 148.4000 115.0000 142.4000 142.4000 1,044,495
Apr 01, 2014 155.8000 173.6000 102.4000 116.8000 116.8000 2,098,785
Mar 01, 2014 200.4000 209.0000 142.4000 152.8000 152.8000 2,017,390
Feb 01, 2014 188.0000 216.8000 170.0000 205.6000 205.6000 2,105,485
Jan 01, 2014 226.0000 247.6000 163.4000 189.0000 189.0000 5,330,400
Dec 01, 2013 175.0000 230.8000 162.0000 221.4000 221.4000 3,619,930
Nov 01, 2013 150.0000 273.0000 132.2000 177.6000 177.6000 10,327,500